The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer

Cancer

Volumn 110, Issue 2, 2007, Pages 363-368

  Schild, Steven E ^a,d   Mandrekar, Sumithra J ^a   Jatoi, Aminah ^a   McGinnis, William L ^b   Stella, Phillip J ^c   Deming, Richard L ^a   Jett, James R ^a   Garces, Yolanda I ^a   Allen, Katie L ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

^b Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^c Michigan Cancer Research Consortium   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Cisplatin; Concurrent therapy; Elderly; Etoposide; Nonsmall cell lung cancer; North Central Cancer Treatment Group; Radiation therapy; Severe toxicity; Stage III

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DYSPNEA; ELDERLY CARE; ESOPHAGITIS; FEMALE; HUMAN; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION INJURY; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RADIOTHERAPY; SURVIVAL RATE;

EID: 34547174880     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22780     Document Type: Article

References (21)

1. Perez C. Non-small cell carcinoma of the lung: dose-time parameters. Cancer Treatment Symp. 1985;2:131-142.
2. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874-1881.
3. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year fol-low-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210-1215.
4. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198-205.
5. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326: 524-530.
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699.
7. Komaki R, Seiferheld W, Curran W, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Proceedings of the 42nd Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys. 2000;48:113. Abstract 5.
8. Surveillance, Epidemiology, and End Results Program, National Cancer Institute. Available at URL: http://seer. cancer.gov/csr/1975_2004/ results_single/sect_01_table.11_ 2pgs.pdf Accessed May 23, 2007.
9. Rocha Lima CM, Herndon JE 2nd, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002;94:181-187.
10. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201-3206.
11. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer (LA NSCLC) benefit from combined modality therapy, secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol. 2002;21:299a. Abstract 1193.
12. Jeremic B, Shibamoto Y, Milicic B, et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;44:343-348.
13. Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol. 2005;35:195-201.
14. Schild SE, Stella PJ, Geyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:370-378.
15. Bonner JA, McGinnis WL, Stella PJ, et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III study. Cancer. 1998;82:1037-1048.
16. Videtic G, Vokes E, Turrisi A, et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. Proc Am Soc Clin Oncol. 2003;22. Abstract 2557.
17. [No authors listed]. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
18. Langer C, Scott C, Byhardt R, et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer. 2000;29:104. Abstract 340.
19. Wikipedia. Available at URL: http://en.wikipedia.org/wiki/elderly Accessed May 23, 2007.
20. Pepe C, Hasan B, Winton T, et al. Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR. 10. 2006 ASCO Annual Meeting proceedings, part 1. J Clin Oncol. 2006;24. Abstract 7009.
21. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:9113-9119.